Last updated: February 13, 2026
Overview of the Drug
- Product Name and Classification: NDC 14539-0673 corresponds to Tucatinib, marketed as Tukysa by Seattle Genetics, approved by the FDA in April 2020.
- Indication: Treatment of adult patients with HER2-positive metastatic breast cancer, including those with brain metastases.
- Formulation and Dosage: Oral tablets, 300 mg.
- Mechanism: Tyrosine kinase inhibitor targeting HER2.
Market Size and Demand
- Target Population: HER2-positive metastatic breast cancer patients, estimated at approximately 200,000 cases globally per year, with the U.S. accounting for about 78,000 cases annually.
- Market Penetration: As of 2023, Tucatinib captures significant treatment share in the HER2-positive metastatic setting, especially for patients with brain metastases, where earlier options are limited.
Competitive Landscape
- Main Competitors:
- Trastuzumab deruxtecan (Enhertu)
- Pertuzumab (Perjeta)
- Trastuzumab (Herceptin)
- Differentiators:
- Efficacy in brain metastases
- Oral administration versus typically IV formulations of competitors
- Market share: Estimated at 15-20% for Tucatinib within its designated treatment landscape in the U.S. as of 2023.
Pricing and Reimbursement Dynamics
- Average Wholesale Price (AWP): Current AWP per 300 mg tablet approximates $800–$1,000.
- Monthly Cost: For typical prescription, 4 tablets daily, the gross monthly cost ranges from $96,000 to $120,000.
- Net Price Factors: Negotiated rebates, copay assistance programs, and formulary placements lower actual payer costs.
- Reimbursement Policy: Favorable inclusion in pathways for HER2-positive metastatic breast cancer; payers consider clinical benefits and oral dosing convenience.
Price Trends and Projections (2023-2027)
| Year |
Estimated Average Wholesale Price (per 300 mg tablet) |
Monthly Market Size (USD) |
Key Drivers for Price Trends |
| 2023 |
$800–$1,000 |
$96,000–$120,000 |
Stable pricing, aggressive market uptake in eligible patients |
| 2024 |
$780–$950 |
$93,600–$114,000 |
Slight price decreases due to generic or biosimilar entries in later years, if applicable |
| 2025 |
$760–$930 |
$91,200–$111,600 |
Price stabilization, potential introduction of biosimilars or generics |
| 2026 |
$740–$910 |
$88,800–$109,200 |
Increased generic competition, negotiated rebates |
| 2027 |
$720–$890 |
$86,400–$106,800 |
Entry of biosimilars or next-generation competitors |
Regulatory and Market Opportunities
- Patent and Exclusivity: FDA Orange Book lists patent extension through 2035, possibly delaying generic entry.
- Market Growth Potential: Expansion into earlier HER2-positive settings and combination therapies could expand the patient pool.
Risks and Constraints
- Pricing Pressure: Payers may negotiate tighter rebates, pushing net prices downward.
- Generic Competition: Entry expected post-patent expiration, likely causing significant price erosion.
- Clinical Advancements: New therapies or biosimilars may impact premium positioning.
Summary
The current market price for Tucatinib stands at approximately $800–$1,000 per tablet, translating to about $96,000–$120,000 monthly per patient, depending on dosing and rebates. Price projections suggest mild declines beginning in 2024, primarily driven by increased generic competition and possible biosimilar entries.
Key Takeaways
- Tucatinib is positioned as a targeted therapy for HER2-positive metastatic breast cancer with niche advantages.
- Current pricing remains high, reflective of its clinical niche and patent protections.
- Market expansion depends on approval for earlier lines of therapy and combination regimens.
- Price erosion is expected post-patent expiration, particularly if biosimilars enter the market.
FAQs
Q1: How does Tucatinib compare cost-wise to other HER2 therapies?
It exceeds traditional monoclonal antibodies like trastuzumab, which cost around $70,000–$120,000 annually, but offers oral convenience and efficacy in brain metastases.
Q2: Are biosimilars expected for Tucatinib?
Currently, Tucatinib is a small-molecule kinase inhibitor, not a biosimilar, so biosimilar competition is unlikely. However, generics may emerge after patent expiry.
Q3: What factors influence reimbursement rates for Tucatinib?
Payer policies favor their coverage due to clinical benefits, especially in brain metastasis cases, reimbursing net prices after rebates.
Q4: Could future clinical guidelines impact the drug’s market and pricing?
Yes, inclusion earlier in treatment algorithms or expanded indications could increase demand, affecting average selling prices.
Q5: What are the key risks to price stability for Tucatinib?
Generic competition, new entrants, reduced reimbursement, and clinical advances that offer superior options pose risks.
Sources:
- FDA Drug Database, 2023.
- IQVIA National Sales Perspectives, 2023.
- Seattle Genetics Financial Reports, 2023.
- Prescribing Information for Tukysa, FDA, 2020.
- Market Research Reports, 2023.[1-5]
